Strand and ChemAxon Enter into Collaboration
News Jan 12, 2006
Strand Life Sciences has announced that it has integrated ChemAxon’s JChem suite of software with admetis, its tool for modeling and predicting drug-relevant properties of molecules in silico. The integrated offering will be launched in the early part of Q1 2006.
admetis is a tool for modeling and predicting drug-relevant properties of molecules in silico.
It is designed to give users the power to build custom models using their own data. This is made possible through model-building workflows based on Strand's expertise in in silico model building.
admetis comes packaged with its pre-built models, truPK and truTox, for predicting Bioavailability, Protein binding, Volume distribution, Elimination half life, Rate of absorption and hERG binding.
admetis has an extensive data mining and visualization module that supports an embedded chemical structure viewer.
The inclusion of ChemAxon’s JChem toolkit provides admetis with a chemically aware data management and search framework.
admetis users will be able to enjoy chemical editing and visualization capabilities as well as the power to build complex queries using structural and non-structural data.
"admetis couples pre-built models with a workflow-based modeling platform making it a distinct offering," said Kas Subramanian, CSO, Strand Life Sciences.
"Some of the key features of JChem directly address the requests from our prospects and customers. We believe that this integration will benefit our customers," he added.
"We are happy that we have such a good fit with the admetis offering and given Strands expertise and ambitious plans for future development we see a bright future for the collaboration," said Ferenc Csizmadia, CEO of ChemAxon.
Chemical Compound Class Possesses Potential for Treating Zika VirusNews
A new and promising class of chemical compounds has major potential for treating Zika virus and respiratory syncytial virus, or RSV, according to a new study.READ MORE
Lab Innovations 2018 – Registration Opens and Keynotes AnnouncedNews
Learn and earn CPD points at the UK’s only lab-dedicated showcase and scientific seminar series.READ MORE
Anti-TNF Drug Offers Hope to Patients with Disabling Hand ConditionNews
Scientists have found that injection of the anti-TNF drug adalimumab into Dupuytren's disease nodules results in the reduction of the cell characteristics responsible for progression of Dupuytren's disease.READ MORE